Loading...
34 colchicine COVID-19 controlled studies, 17 RCTs
https://c19colchicine.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hunt 68%
0.32 [0.15-0.67]
death
Improvement, RR [CI] Treatment Control Deftereos (RCT) 77%
0.23 [0.03-1.97]
death
1/55
4/50
Deftereos (RCT) 82%
0.18 [0.02-1.50]
ventilation
1/55
5/50
Deftereos (RCT) 87%
0.13 [0.01-0.97]
progression
1/55
7/50
Lopes (DB RCT) 80%
0.20 [0.01-4.03]
death
0/36
2/36
Lopes (DB RCT) 50%
0.50 [0.10-2.56]
ICU
2/36
4/36
Lopes (DB RCT) 22%
0.78 [0.64-0.94]
hosp. time
36 (n)
36 (n)
Brunetti (PSM) 73%
0.27 [0.08-0.89]
death
3/33
11/33
Brunetti (PSM) 73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Scarsi 85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT) 23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón 35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu 42%
0.58 [0.40-0.85]
death
16/34
63/78
Sandhu 53%
0.47 [0.33-0.67]
ventilation
16/34
68/68
Sandhu 42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Rodriguez-Nava 6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale -7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU) 23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT1
Valerio Pas.. (ICU) 40%
0.60 [0.38-0.95]
ICU
35 (n)
30 (n)
ICU patients CT1
Tardif (DB RCT) 44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
Tardif (DB RCT) 20%
0.80 [0.62-1.03]
death/hosp.
104/2,235
131/2,253
Tardif (DB RCT) 47%
0.53 [0.25-1.09]
ventilation
11/2,235
21/2,253
Tardif (DB RCT) 20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Mareev 80%
0.20 [0.01-4.01]
death
0/21
2/22
Mareev 50%
0.50 [0.24-1.04]
no recov.
21 (n)
22 (n)
Mareev 71%
0.29 [0.13-0.63]
no recov.
21 (n)
22 (n)
Mareev 67%
0.33 [0.10-1.07]
no recov.
21 (n)
22 (n)
Mareev 26%
0.74 [0.53-1.04]
hosp. time
21 (n)
22 (n)
García-Posada 57%
0.43 [0.16-0.84]
death
48/99
59/110
CT1
Manenti (PSW) 76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Manenti (PSW) 44%
0.56 [0.31-1.00]
no recov.
71 (n)
70 (n)
Mostafaie (RCT) 83%
0.17 [0.02-1.34]
death
1/60
6/60
CT1
Mostafaie (RCT) 35%
0.65 [0.53-0.81]
hosp. time
59 (n)
54 (n)
CT1
Recovery C.. (RCT) -1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
Recovery C.. (RCT) -18%
1.18 [0.99-1.40]
ventilation
259/3,815
228/3,962
Recovery C.. (RCT) -2%
1.02 [0.96-1.09]
death/int.
1,344/5,342
1,343/5,469
Recovery C.. (RCT) -2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Hueda-Zavaleta 54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian 96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT1
Gaitán-Dua.. (RCT) 22%
0.78 [0.44-1.36]
death
22/153
28/161
CT1
Pascual-Fi.. (RCT) 80%
0.20 [0.01-4.03]
death
0/52
2/51
Pascual-Fi.. (RCT) 80%
0.20 [0.01-4.03]
ventilation
0/52
2/51
Pascual-Fi.. (RCT) 51%
0.49 [0.09-2.56]
ICU
2/52
4/51
Pascual-Fi.. (RCT) 87%
0.13 [0.01-0.71]
7-point status
3/52
7/51
Pascual-Fi.. (RCT) 80%
0.20 [0.01-4.03]
7-point status
0/52
2/51
Pascual-Fi.. (RCT) -15%
1.15 [0.87-1.51]
hosp. time
52 (n)
51 (n)
Dorward (RCT) 70%
0.30 [0.01-7.37]
death
0/156
1/120
Dorward (RCT) -30%
1.30 [0.42-3.84]
death/hosp.
6/156
4/133
Dorward (RCT) 22%
0.78 [0.30-1.73]
death/hosp.
6/156
119/1,145
Dorward (RCT) -6%
1.06 [0.81-1.39]
no recov.
156 (n)
133 (n)
Absalón-.. (DB RCT) 29%
0.71 [0.21-2.40]
death
4/56
6/60
Absalón-.. (DB RCT) 17%
0.83 [0.35-1.93]
progression
56 (n)
60 (n)
Absalón-.. (DB RCT) -13%
1.13 [0.76-1.66]
no recov.
56 (n)
60 (n)
Diaz (RCT) 12%
0.88 [0.70-1.12]
death
131/640
142/639
Diaz (RCT) 17%
0.83 [0.67-1.02]
death/int.
160/640
184/639
Diaz (RCT) 52%
0.48 [0.18-1.27]
death/int.
6/93
13/102
Diaz (RCT) 17%
0.83 [0.64-1.07]
death
98/515
140/634
Diaz (RCT) 25%
0.75 [0.60-0.95]
death/int.
117/515
181/634
Alsultan (RCT) 36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş 13%
0.87 [0.46-1.64]
death
16/165
19/171
Karakaş 16%
0.84 [0.55-1.29]
ICU
30/165
37/171
Karakaş 25%
0.75 [0.65-0.87]
hosp. time
165 (n)
171 (n)
Pourdowlat (RCT) 73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Pourdowlat (RCT) 38%
0.62 [0.41-0.94]
no recov.
89 (n)
63 (n)
Pourdowlat (RCT) 22%
0.78 [0.60-1.00]
no recov.
89 (n)
63 (n)
Gorial (RCT) 67%
0.33 [0.04-3.14]
death
1/80
3/80
Gorial (RCT) 63%
0.37 [0.21-0.67]
no recov.
80 (n)
80 (n)
Pimenta B.. (RCT) 79%
0.21 [0.01-4.05]
death
0/14
2/16
Pimenta B.. (RCT) 85%
0.15 [0.01-2.69]
no improv.
0/14
3/16
Jalal (RCT) 24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Cecconi (DB RCT) 29%
0.71 [0.28-1.79]
death
7/119
10/120
Cecconi (DB RCT) 50%
0.50 [0.18-1.43]
ventilation
5/119
10/120
Cecconi (DB RCT) 21%
0.79 [0.38-1.67]
ICU
11/119
14/120
Cecconi (DB RCT) 15%
0.85 [0.50-1.43]
NIV/ICU/vent./death
21/119
25/120
Monserrat V.. (PSM) 80%
0.20 [0.02-0.93]
death
n/a
n/a
Topless 23%
0.77 [0.56-1.07]
death
Oztas -406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Oztas -73%
1.73 [0.96-3.11]
symp. case
29/635
17/643
Oztas -24%
1.24 [0.81-1.92]
cases
43/635
35/643
colchicine COVID-19 outcomes c19colchicine.com Jul 2022
1 CT: study uses combined treatment Favors colchicine
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit
